Healthcare Market Research Reports & Industry Analysis

Healthcare refers to the field associated with maintaining or restoring patients’ health. These days’ Healthcare Industry falls into a lashing of discrete sub-sectors, and ancillary goods and services. Ranging from therapeutic equipment to medicinal drugs, medical tourism to sickness insurance, the Healthcare Market has been one of the most swiftly expanding sectors within the globe’s economic system.

Global Healthcare spending contributes close to 10% to the whole world’s GDP, though it varies noticeably with geography. Thus, the Western world’s average healthcare costs are far greater in contrast to those in the developing economies. North America alone is in charge of circa a half of the world’s overall spending on healthcare services. With budgets curtailments and growing costs, technology advances are increasingly taking a new meaning in the global Healthcare universe.

The research reports offer comprehensive insights into the market sizing, structure and dynamics of the Healthcare Industry based on various geographies, as well as in-depth market segmentation. The research reports incorporated in this Catalogue closely investigate the competition in the Healthcare Market, besides profiling countless market participants. Moreover, tomorrow's healthcare-related challenges are addressed, as well as projections into the future are provided in the research reports.

Publications found: 69,579
Sort by:

Poly [ADP Ribose] Polymerase 3 (ADP Ribosyltransferase Diphtheria Toxin Like 3 or NAD(+) ADP Ribosyltransferase 3 or Poly[ADP Ribose] Synthase 3 or PARP3 or EC 2.4.2.30) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Poly [ADP Ribose] Polymerase 3 (ADP Ribosyltransferase Diphtheria Toxin Like 3 or NAD(+) ADP Ribosyltransferase 3 or Poly[ADP Ribose] Synthase 3 or PARP3 or EC 2.4.2.30) Drugs in Development by Therap...

May 2022 36 pages

Potassium Voltage Gated Channel Subfamily C Member 1 (Voltage Gated Potassium Channel Subunit Kv3.1 or Voltage Gated Potassium Channel Subunit Kv4 or KCNC1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Potassium Voltage Gated Channel Subfamily C Member 1 (Voltage Gated Potassium Channel Subunit Kv3.1 or Voltage Gated Potassium Channel Subunit Kv4 or KCNC1) Drugs in Development by Therapy Areas and I...

May 2022 40 pages

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) Drugs in Development by...

May 2022 49 pages

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) Drugs in Development by Therapy Areas and Indi...

May 2022 46 pages

Prostaglandin E Synthase (Microsomal Glutathione S Transferase 1 Like 1 or Microsomal Prostaglandin E Synthase 1 or p53 Induced Gene 12 Protein or PTGES or EC 5.3.99.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Prostaglandin E Synthase (Microsomal Glutathione S Transferase 1 Like 1 or Microsomal Prostaglandin E Synthase 1 or p53 Induced Gene 12 Protein or PTGES or EC 5.3.99.3) Drugs in Development by Therapy...

May 2022 43 pages

Prostatic Acid Phosphatase (5 Nucleotidase or Ecto 5 Nucleotidase or Thiamine Monophosphatase or ACPP or EC 3.1.3.2 or EC 3.1.3.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Prostatic Acid Phosphatase (5 Nucleotidase or Ecto 5 Nucleotidase or Thiamine Monophosphatase or ACPP or EC 3.1.3.2 or EC 3.1.3.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, R...

May 2022 35 pages

Proteasome Subunit Beta Type 8 (Low Molecular Mass Protein 7 or Macropain Subunit C13 or Multicatalytic Endopeptidase Complex Subunit C13 or Proteasome Component C13 or Proteasome Subunit Beta 5i or PSMB8 or EC 3.4.25.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Proteasome Subunit Beta Type 8 (Low Molecular Mass Protein 7 or Macropain Subunit C13 or Multicatalytic Endopeptidase Complex Subunit C13 or Proteasome Component C13 or Proteasome Subunit Beta 5i or P...

May 2022 35 pages

Protein Arginine N Methyltransferase 5 (Shk1 Kinase Binding Protein 1 Homolog or Jak Binding Protein 1 or Histone Arginine N Methyltransferase PRMT5 or 72 kDa ICln Binding Protein or PRMT5 or EC 2.1.1.320) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Protein Arginine N Methyltransferase 5 (Shk1 Kinase Binding Protein 1 Homolog or Jak Binding Protein 1 or Histone Arginine N Methyltransferase PRMT5 or 72 kDa ICln Binding Protein or PRMT5 or EC 2.1.1...

May 2022 52 pages

Protein Mdm4 (Double Minute 4 Protein or Mdm2 Like p53 Binding Protein or Protein Mdmx or p53 Binding Protein Mdm4 or MDM4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Protein Mdm4 (Double Minute 4 Protein or Mdm2 Like p53 Binding Protein or Protein Mdmx or p53 Binding Protein Mdm4 or MDM4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Mol...

May 2022 35 pages

Protein O GlcNAcase (Beta Hexosaminidase or Beta N Acetylhexosaminidase or N Acetyl Beta Glucosaminidase or Meningioma Expressed Antigen 5 or Nuclear Cytoplasmic O GlcNAcase And Acetyltransferase or MGEA5 or EC 3.2.1.169) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Protein O GlcNAcase (Beta Hexosaminidase or Beta N Acetylhexosaminidase or N Acetyl Beta Glucosaminidase or Meningioma Expressed Antigen 5 or Nuclear Cytoplasmic O GlcNAcase And Acetyltransferase or M...

May 2022 37 pages

Proto Oncogene Tyrosine Protein Kinase Receptor Ret (Cadherin Family Member 12 or Proto Oncogene c Ret or RET or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Proto Oncogene Tyrosine Protein Kinase Receptor Ret (Cadherin Family Member 12 or Proto Oncogene c Ret or RET or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, M...

May 2022 80 pages

Pyruvate Kinase PKM (Cytosolic Thyroid Hormone Binding Protein or Pyruvate Kinase Muscle Isozyme or Opa Interacting Protein 3 or Pyruvate Kinase 2-3 or Tumor M2 PK or PKM2 or Thyroid Hormone Binding Protein 1 or p58 or PKM or EC 2.7.1.40) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Pyruvate Kinase PKM (Cytosolic Thyroid Hormone Binding Protein or Pyruvate Kinase Muscle Isozyme or Opa Interacting Protein 3 or Pyruvate Kinase 2-3 or Tumor M2 PK or PKM2 or Thyroid Hormone Binding P...

May 2022 36 pages

Receptor Activity Modifying Protein 2 (Calcitonin Receptor Like Receptor Activity Modifying Protein 2 or CRLR Activity Modifying Protein 2 or RAMP2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Receptor Activity Modifying Protein 2 (Calcitonin Receptor Like Receptor Activity Modifying Protein 2 or CRLR Activity Modifying Protein 2 or RAMP2) Drugs in Development by Therapy Areas and Indicatio...

May 2022 38 pages

Receptor Type Tyrosine Protein Kinase FLT3 (FMS Like Tyrosine Kinase 3 or FL Cytokine Receptor or Stem Cell Tyrosine Kinase 1 or Fetal Liver Kinase 2 or CD135 or FLT3 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Receptor Type Tyrosine Protein Kinase FLT3 (FMS Like Tyrosine Kinase 3 or FL Cytokine Receptor or Stem Cell Tyrosine Kinase 1 or Fetal Liver Kinase 2 or CD135 or FLT3 or EC 2.7.10.1) Drugs in Developm...

May 2022 113 pages

Receptor Tyrosine Protein Kinase ERBB 2 (Metastatic Lymph Node Gene 19 Protein or Proto Oncogene Neu or Proto Oncogene C ErbB 2 or Tyrosine Kinase Type Cell Surface Receptor HER2 or p185erbB2 or HER2 or CD340 or ERBB2 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

Receptor Tyrosine Protein Kinase ERBB 2 (Metastatic Lymph Node Gene 19 Protein or Proto Oncogene Neu or Proto Oncogene C ErbB 2 or Tyrosine Kinase Type Cell Surface Receptor HER2 or p185erbB2 or HER2...

May 2022 173 pages

Retinal Specific ATP Binding Cassette Transporter (ATP Binding Cassette Sub Family A Member 4 or RIM ABC Transporter or Stargardt Disease Protein or ABCA4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Retinal Specific ATP Binding Cassette Transporter (ATP Binding Cassette Sub Family A Member 4 or RIM ABC Transporter or Stargardt Disease Protein or ABCA4) Drugs in Development by Therapy Areas and In...

May 2022 41 pages

Retinoic Acid Receptor RXR Alpha (Nuclear Receptor Subfamily 2 Group B Member 1 or Retinoid X Receptor Alpha or NR2B1 or RXRA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Retinoic Acid Receptor RXR Alpha (Nuclear Receptor Subfamily 2 Group B Member 1 or Retinoid X Receptor Alpha or NR2B1 or RXRA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA,...

May 2022 39 pages

Retinoid Isomerohydrolase (All Trans Retinyl Palmitate Hydrolase or Retinal Pigment Epithelium Specific 65 kDa Protein or Retinol Isomerase or RPE65 or EC 3.1.1.64) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Retinoid Isomerohydrolase (All Trans Retinyl Palmitate Hydrolase or Retinal Pigment Epithelium Specific 65 kDa Protein or Retinol Isomerase or RPE65 or EC 3.1.1.64) Drugs in Development by Therapy Are...

May 2022 37 pages

Sigma Non Opioid Intracellular Receptor 1 (Aging Associated Gene 8 Protein or SR31747 Binding Protein or Sigma 1 Type Opioid Receptor or SIGMAR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sigma Non Opioid Intracellular Receptor 1 (Aging Associated Gene 8 Protein or SR31747 Binding Protein or Sigma 1 Type Opioid Receptor or SIGMAR1) Drugs in Development by Therapy Areas and Indications,...

May 2022 59 pages

Sodium Channel Protein Type 1 Subunit Alpha (Sodium Channel Protein Brain I Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.1 or SCN1A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium Channel Protein Type 1 Subunit Alpha (Sodium Channel Protein Brain I Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.1 or SCN1A) Drugs in Development by Therapy Areas and Indic...

May 2022 56 pages

Sodium Channel Protein Type 10 Subunit Alpha (Peripheral Nerve Sodium Channel 3 or Voltage Gated Sodium Channel Subunit Alpha Nav1.8 or SCN10A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium Channel Protein Type 10 Subunit Alpha (Peripheral Nerve Sodium Channel 3 or Voltage Gated Sodium Channel Subunit Alpha Nav1.8 or SCN10A) Drugs in Development by Therapy Areas and Indications, S...

May 2022 62 pages

Sodium Channel Protein Type 11 Subunit Alpha (Peripheral Nerve Sodium Channel 5 or Sodium Channel Protein Type XI Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.9 or SCN11A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium Channel Protein Type 11 Subunit Alpha (Peripheral Nerve Sodium Channel 5 or Sodium Channel Protein Type XI Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.9 or SCN11A) Drugs in...

May 2022 36 pages

Sodium Channel Protein Type 2 Subunit Alpha (HBSC II or Sodium Channel Protein Brain II Subunit Alpha or Sodium Channel Protein Type II Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.2 or SCN2A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium Channel Protein Type 2 Subunit Alpha (HBSC II or Sodium Channel Protein Brain II Subunit Alpha or Sodium Channel Protein Type II Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1...

May 2022 51 pages

Sodium Channel Protein Type 3 Subunit Alpha (Voltage Gated Sodium Channel Subtype III or Voltage Gated Sodium Channel Subunit Alpha Nav1.3 or SCN3A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium Channel Protein Type 3 Subunit Alpha (Voltage Gated Sodium Channel Subtype III or Voltage Gated Sodium Channel Subunit Alpha Nav1.3 or SCN3A) Drugs in Development by Therapy Areas and Indicatio...

May 2022 47 pages

Sodium Channel Protein Type 4 Subunit Alpha (Sodium Channel Protein Skeletal Muscle Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.4 or SCN4A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium Channel Protein Type 4 Subunit Alpha (Sodium Channel Protein Skeletal Muscle Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.4 or SCN4A) Drugs in Development by Therapy Areas a...

May 2022 45 pages

Sodium Channel Protein Type 5 Subunit Alpha (Sodium Channel Protein Cardiac Muscle Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.5 or SCN5A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium Channel Protein Type 5 Subunit Alpha (Sodium Channel Protein Cardiac Muscle Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.5 or SCN5A) Drugs in Development by Therapy Areas an...

May 2022 49 pages

Sodium Channel Protein Type 9 Subunit Alpha (Neuroendocrine Sodium Channel or Peripheral Sodium Channel 1 or Voltage Gated Sodium Channel Subunit Alpha Nav1.7 or SCN9A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium Channel Protein Type 9 Subunit Alpha (Neuroendocrine Sodium Channel or Peripheral Sodium Channel 1 or Voltage Gated Sodium Channel Subunit Alpha Nav1.7 or SCN9A) Drugs in Development by Therapy...

May 2022 100 pages

Sodium Dependent Noradrenaline Transporter (Norepinephrine Transporter or NET or Solute Carrier Family 6 Member 2 or SLC6A2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium Dependent Noradrenaline Transporter (Norepinephrine Transporter or NET or Solute Carrier Family 6 Member 2 or SLC6A2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Mo...

May 2022 125 pages

Solute Carrier Family 12 Member 2 (Basolateral Na-K-Cl Symporter or Bumetanide Sensitive Sodium (Potassium) Chloride Cotransporter 1 or SLC12A2 or NKCC1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Solute Carrier Family 12 Member 2 (Basolateral Na-K-Cl Symporter or Bumetanide Sensitive Sodium (Potassium) Chloride Cotransporter 1 or SLC12A2 or NKCC1) Drugs in Development by Therapy Areas and Indi...

May 2022 35 pages

Solute Carrier Family 12 Member 3 (Na-Cl Cotransporter or NCC or Na-Cl Symporter or Thiazide Sensitive Sodium Chloride Cotransporter or SLC12A3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Solute Carrier Family 12 Member 3 (Na-Cl Cotransporter or NCC or Na-Cl Symporter or Thiazide Sensitive Sodium Chloride Cotransporter or SLC12A3) Drugs in Development by Therapy Areas and Indications,...

May 2022 43 pages

Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) Drugs in Development by Therapy Areas and Indi...

May 2022 52 pages

Sphingosine 1-Phosphate Receptor 5 (Endothelial Differentiation G Protein Coupled Receptor 8 or Sphingosine 1 Phosphate Receptor Edg 8 or S1PR5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sphingosine 1-Phosphate Receptor 5 (Endothelial Differentiation G Protein Coupled Receptor 8 or Sphingosine 1 Phosphate Receptor Edg 8 or S1PR5) Drugs in Development by Therapy Areas and Indications,...

May 2022 37 pages

Stimulator Of Interferon Genes Protein (Endoplasmic Reticulum Interferon Stimulator or Mediator Of IRF3 Activation or Transmembrane Protein 173 or STING or TMEM173) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Stimulator Of Interferon Genes Protein (Endoplasmic Reticulum Interferon Stimulator or Mediator Of IRF3 Activation or Transmembrane Protein 173 or STING or TMEM173) Drugs in Development by Therapy Are...

May 2022 101 pages

Synaptic Vesicular Amine Transporter (Monoamine Transporter or Solute Carrier Family 18 Member 2 or Vesicular Amine Transporter 2 or VAT2 or SLC18A2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Synaptic Vesicular Amine Transporter (Monoamine Transporter or Solute Carrier Family 18 Member 2 or Vesicular Amine Transporter 2 or VAT2 or SLC18A2) Drugs in Development by Therapy Areas and Indicati...

May 2022 36 pages

T Cell Immunoreceptor With Ig And ITIM Domains (V Set And Immunoglobulin Domain Containing Protein 9 or V Set And Transmembrane Domain Containing Protein 3 or TIGIT) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

T Cell Immunoreceptor With Ig And ITIM Domains (V Set And Immunoglobulin Domain Containing Protein 9 or V Set And Transmembrane Domain Containing Protein 3 or TIGIT) Drugs in Development by Therapy Ar...

May 2022 77 pages

Tankyrase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 5 or Poly [ADP Ribose] Polymerase 5A or TRF1 Interacting Ankyrin Related ADP Ribose Polymerase or TNKS or EC 2.4.2.30) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tankyrase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 5 or Poly [ADP Ribose] Polymerase 5A or TRF1 Interacting Ankyrin Related ADP Ribose Polymerase or TNKS or EC 2.4.2.30) Drugs in Development by...

May 2022 37 pages

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) Drugs in Development by Therapy Areas and Indications, Stages, MoA, R...

May 2022 76 pages

Thyroid Hormone Receptor Alpha (Nuclear Receptor Subfamily 1 Group A Member 1 or V erbA Related Protein 7 or c erbA 1 or c erbA Alpha or EAR7 or THRA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Thyroid Hormone Receptor Alpha (Nuclear Receptor Subfamily 1 Group A Member 1 or V erbA Related Protein 7 or c erbA 1 or c erbA Alpha or EAR7 or THRA) Drugs in Development by Therapy Areas and Indicat...

May 2022 39 pages

Thyroid Hormone Receptor Beta (Nuclear Receptor Subfamily 1 Group A Member 2 or c erbA 2 or c erbA Beta or ERBA2 or THRB) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Thyroid Hormone Receptor Beta (Nuclear Receptor Subfamily 1 Group A Member 2 or c erbA 2 or c erbA Beta or ERBA2 or THRB) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molec...

May 2022 59 pages

Transcriptional Enhancer Factor TEF-1 (NTEF-1 or Protein GT-IIC or TEA Domain Family Member 1 or Transcription Factor 13 or TEAD1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Transcriptional Enhancer Factor TEF-1 (NTEF-1 or Protein GT-IIC or TEA Domain Family Member 1 or Transcription Factor 13 or TEAD1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, R...

May 2022 37 pages

Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Drugs in Development by Therapy A...

May 2022 42 pages

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) Drugs in Development by Therapy Areas and Ind...

May 2022 40 pages

Translocator Protein (Mitochondrial Benzodiazepine Receptor or PKBS or Peripheral Type Benzodiazepine Receptor or PBR or TSPO) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Translocator Protein (Mitochondrial Benzodiazepine Receptor or PKBS or Peripheral Type Benzodiazepine Receptor or PBR or TSPO) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA,...

May 2022 35 pages

Tripeptidyl Peptidase 1 (Tripeptidyl Aminopeptidase or Lysosomal Pepstatin Insensitive Protease or Cell Growth Inhibiting Gene 1 Protein or TPP1 or EC 3.4.14.9) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tripeptidyl Peptidase 1 (Tripeptidyl Aminopeptidase or Lysosomal Pepstatin Insensitive Protease or Cell Growth Inhibiting Gene 1 Protein or TPP1 or EC 3.4.14.9) Drugs in Development by Therapy Areas a...

May 2022 35 pages

Tumor Necrosis Factor Ligand Superfamily Member 10 (Apo 2 Ligand or TNF Related Apoptosis Inducing Ligand or Protein TRAIL or CD253 or TNFSF10) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tumor Necrosis Factor Ligand Superfamily Member 10 (Apo 2 Ligand or TNF Related Apoptosis Inducing Ligand or Protein TRAIL or CD253 or TNFSF10) Drugs in Development by Therapy Areas and Indications, S...

May 2022 36 pages

Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or RANKL or CD254 or TNFSF11) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoproteger...

May 2022 71 pages

Tumor Necrosis Factor Ligand Superfamily Member 13 (A Proliferation Inducing Ligand or APRIL or TNF And APOL Related Leukocyte Expressed Ligand 2 or TNF Related Death Ligand 1 or CD256 or TNFSF13) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tumor Necrosis Factor Ligand Superfamily Member 13 (A Proliferation Inducing Ligand or APRIL or TNF And APOL Related Leukocyte Expressed Ligand 2 or TNF Related Death Ligand 1 or CD256 or TNFSF13) Dru...

May 2022 37 pages

Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) Drug...

May 2022 37 pages

Tumor Necrosis Factor Ligand Superfamily Member 4 (Glycoprotein Gp34 or OX40 Ligand or TAX Transcriptionally Activated Glycoprotein 1 or CD252 or TNFSF4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tumor Necrosis Factor Ligand Superfamily Member 4 (Glycoprotein Gp34 or OX40 Ligand or TAX Transcriptionally Activated Glycoprotein 1 or CD252 or TNFSF4) Drugs in Development by Therapy Areas and Indi...

May 2022 38 pages

Tumor Necrosis Factor Receptor Superfamily Member 1B (Tumor Necrosis Factor Receptor 2 or p75 or p80 TNF Alpha Receptor or CD120b or TNFRSF1B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tumor Necrosis Factor Receptor Superfamily Member 1B (Tumor Necrosis Factor Receptor 2 or p75 or p80 TNF Alpha Receptor or CD120b or TNFRSF1B) Drugs in Development by Therapy Areas and Indications, St...

May 2022 53 pages

Filters

Search

Categories

836
28
208
156
143
133
127
93
65,439
803
718
772
123

Publishers

179
1
239
158
389
103
444
148
425
3
202
3
6
1,620
487
76
123
208
111
25
212
1,049
378
23
40
68
472
277
34
29,954
248
501
3,036
1
1
2
3
16
536
361
1
1,357
1,790
60
1,696
8
8,921
2,212
4,495
321
66
3
36
200
29
29
143
42
83
3
281
85
20
6
43
14
1
178
48
359
36
44
10
11
18
168
323
8
3
18
58
901
6
89
12
24
15
1,285
227
128
386
3
74
10
119
228
46
474
26
133
4

Regions

92
58
45
43
41
35
31
30
30
29
28
28
28
26
16
16
14
12
12
10
10
10
9
8
8
8
7
7
7
7
7
6
6
6
6
6
6
6
6
6
6
6
6
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
790
495
2
2
2
117
194
102
53
23
704
26
136
526
174
623
64,568

Price

Date

Pages

Offers

1
280
1
1